Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.

Frame vector. Photo or picture art on vintage wall

The US FDA has stepped up its research on prescription drug advertising. In one week last month, the agency announced four new studies that range from a focus on non-Internet users to disclosures in oncology drug promotions directed to healthcare providers.

The first study, announced in the Federal Register June 12, is looking at ways to modify Rx drug broadcast ads to assure those who do not routinely use the Internet get access to full information about a product's major side effects and contraindications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance